A new editorial paper was published in Oncoscience on May 6, 2024, titled, “Restoring our ubiquitination machinery to overcome resistance in cancer therapy.”
In this new editorial, researchers Xiaoling Li and Ping Mu from the University of Southwestern Medical Center discuss the ubiquitin-proteasome system (UPS), which is usually responsible for regulating protein degradation, important for cellular homeostasis, and crucial in cancer progression. Its ability to regulate the stability of proteins that drive cancer growth and survival indicates its potential as a therapeutic target.
Among the UPS components, ubiquitin-conjugating enzymes, such as ubiquitin-conjugating enzyme E2 J1 (UBE2J1), have emerged as key players in cancer dynamics, especially in prostate cancer (PCa) where therapy resistance is a significant challenge.
“In our recent study, through a comprehensive in vivo library screening, we have identified the role of UBE2J1 in PCa, particularly its involvement in the degradation of the androgen receptor (AR),” explained the authors.
More information:
Xiaoling Li et al, Restoring our ubiquitination machinery to overcome resistance in cancer therapy, Oncoscience (2024). DOI: 10.18632/oncoscience.600
Provided by
Impact Journals LLC
Citation:
Editorial: Restoring our ubiquitination machinery to overcome resistance to cancer therapy (2024, June 10)
retrieved 10 June 2024
from https://medicalxpress.com/news/2024-06-editorial-ubiquitination-machinery-resistance-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
